The assessment of global cardiovascular risk is an essential step in the management of atherosclerotic disease prevention. Among the risk factors to be addressed are hypertension and hyperlipidaemia; these commonly coexist. A neutral or lipid-friendly antihypertensive agent is probably useful in the presence of lipid abnormalities. Similarly, statins have been shown to decrease cardiovascular risk in hypertensive patients. There is also experimental and clinical evidence that statins have blood pressure (BP)-lowering effects. In this review, we discuss the beneficial effects of statins on BP, and provide an overview of the underlying pathophysiology. We also consider the evidence justifying the use of statins in the management of hypertensive patients.
Introduction
The first step in evaluating a patient with dyslipoproteinaemia is calculating the global vascular risk as multiple risk factors are often present. When risk factors coexist their combined effect is much greater than the sum of their individual effects. Multiple relatively mild risk factors can greatly increase the risk of developing coronary heart disease (CHD). 1 Thus, a patient with severe hypercholesterolaemia may be at lower risk than a smoker with moderate hypertension and moderately elevated lipid levels. The risk for cardiovascular events increases considerably when hypertension and dyslipidaemia coexist, but the underlying common pathophysiological mechanisms remain undefined. Dyslipidaemia is commonly diagnosed in patients with hypertension, 2 but owing to the high prevalence of both conditions in the general population, this association should not be regarded as merely coincidental. 3, 4 Lipid abnormalities and hypertension are principal constituents of the metabolic syndrome. 5 Moreover, in cases of secondary hypertension associated with renal dysfunction (renal insufficiency, nephrotic syndrome), hyperlipidaemia is a frequent comorbidity. 6 Therefore, it seems appropriate to treat both conditions by using a lipid-friendly antihypertensive and a lipid-lowering agent. However, clinical experience shows that the implementation of global risk-oriented prevention strategies in hypertensive patients is unsatisfactory, and low-density lipoprotein cholesterol (LDL-C) levels are commonly not on target. 7 In this review, we consider the relationships between hypertension and lipid abnormalities and discuss the clinical and experimental data regarding the effects 3-hydroxy-3-methylglutatyl co-enzyme A (HMG CoA) reductase inhibitors (statins) on blood pressure (BP).
Search strategy
Sources included MEDLINE and EMBASE (last search update performed on 2 January 2006). The search strategy was based on the combination of 'statin', 'HMG-CoA enzyme inhibitor', 'atorvastatin', 'simvastatin', 'lovastatin', 'fluvastatin', 'cerivastatin', 'rosuvastatin' and 'pitavastatin' with either 'BP' or 'hypertension'. References of retrieved articles were also screened.
Do lipid abnormalities predict the risk for hypertension?
In a new analysis from the Physicians' Health Study, 8 elevated levels of total cholesterol (TC) were associated with an increased risk of hypertension in middle-aged and older men. Also, higher levels of high-density lipoprotein cholesterol (HDL-C) were associated with a lower risk of hypertension.
Elevated lipid levels seemed to predate the onset of hypertension by years. Specifically, Halperin et al. prospectively examined data from 3110 participants who were free of hypertension, cardiovascular disease and cancer at baseline. Participants responded to follow-up questionnaires at 6 months and then annually reported the incidence of hypertension, other conditions and health habits. Over an average of 14 years of follow-up, approximately onethird of participants developed hypertension. The authors reported that higher levels of TC, non-HDL-C and the TC/HDL-C ratio were independently associated with a 23% (P ¼ 0.0067), 39% (P ¼ 0.0001) and 54% (Po0.0001) increased risk of incidence hypertension, respectively. 8 In addition, those in the highest quintile of HDL-C had a 32% (P ¼ 0.0002) lower risk of developing hypertension compared with those in the lowest quintile. 8 Hypertension is one of the constituents of the metabolic syndrome together with abdominal obesity, hypertriglyceridaemia, low HDL-C and hyperglycaemia. 9, 10 The common denominator in this syndrome is probably insulin resistance. 9, 11, 12 Free fatty acids are related to insulin resistance and may have a direct effect on hypertension. In the Paris Prospective Study, 13 lipid abnormalities (TC, triglycerides (TG) and free fatty acids) were studied as possible predictors of hypertension in 2968 middleaged non-hypertensive and non-diabetic men followed for 3 years. Confounding factors, including obesity, abdominal fat distribution, serum insulin and glucose levels, were taken into account. The weight increase, a high body mass index (BMI), waist circumference, baseline BP levels, glucose, insulin, TC, TGs and free fatty acids were all univariate predictors of hypertension. After controlling for BMI, waist circumference and weight increase, TC and TGs were not significant risk factors for hypertension. Nevertheless, fasting and 2 h free fatty acid levels were highly significant risk factors for hypertension, when controlled for age, family history of hypertension, alcohol consumption, BMI, iliac circumference and weight change (hazard rate ratio (RR) ¼ 1.73, 95% confidence interval (CI): 1.44-2.08). 13 Further controlling for systolic BP, heart rate and fasting insulin and glucose did not decrease their predictive power (RR ¼ 1.58, 95% CI: 1.30-1.91 comparing the 90th with the 10th percentiles at fasting; RR ¼ 1.54, 95% CI: 1.33-1.79 at 2 h). These independent effects of free fatty acids on hypertension are suggestive of underlying metabolic and haemodynamic derangements related to the metabolic syndrome that lead to an increased pressor response. 13 Fatty acids might contribute to elevated BP in part by actions that enhance a1-adrenoceptor-mediated vascular and pressor reactivity and impair endothelium-dependent dilation. [13] [14] [15] [16] It has been shown that the pre-hypertensive metabolic abnormalities may manifest early in life in normotensive offspring of hypertensive parents. 17 Thus, the metabolic abnormalities associated with a positive family history (FH þ ) of hypertension suggest a genetic predisposition to the 'metabolic hypertensive syndrome'. 13, 18 In a study of 23 lean normal volunteers with a negative (FHÀ, n ¼ 11) or positive family history (FH þ , n ¼ 12) of hypertension, Lopes et al. 19 evaluated the metabolic and haemodynamic responses of acute hyperlipidaemia provoked by 4 h infusion of intralipid and heparin. Lean normotensive FH þ subjects had higher baseline TGs and very-low-density lipoprotein cholesterol levels than FHÀ volunteers (Po0.05). However, non-esterified fatty acids (NEFA) increased similarly in both groups during the infusion of intralipid and heparin. Blood pressure and heart rate significantly increased with acute hyperlipidaemia in all subjects combined (Po0.05). 19 Despite the similar increase in NEFA, mean BP, pulse pressure and pressure-rate product increased significantly in FH þ subjects but not in FHÀ volunteers. The rise of systolic BP in particular was significantly greater in FH þ than in FHÀ volunteers during the acute hyperlipidaemia (1472 vs 1072 mm Hg, Po0.05), 19 indicating that dyslipidaemia characteristic of the metabolic syndrome might cause an increase in BP, especially in subjects with a positive family history of hypertension.
There is evidence that normotensive subjects with hypercholesterolaemia have excessive BP responses to stress tests. 20 In a study involving 15 hypercholesterolaemic (HC) patients and 24 normocholesterolaemic controls, Minami et al. 21 showed that cholesterol-lowering therapy can improve excessive BP responses to stress tests, thus confirming that hypercholesterolaemia plays a role in the regulation of BP. All participants carried out mental arithmetic stress and handgrip tests. Blood pressure was measured during these tests. In HC patients, the tests were repeated at the end of a 12-week treatment with pravastatin 10 mg/day. In HC patients, BP responses to both tests were greater than those of controls. Serum TC, LDL-C and lipid peroxides were significantly decreased in association with the pravastatin treatment. Systolic BP to mental arithmetic tests and systolic BP/diastolic BP to handgrip tests decreased (Po0.01, Po0.01/Po0.02, respectively) after pravastatin treatment. 21 Hypertension and dyslipidaemia: a genetic link? Patients with a high BP often have an abnormal serum lipid profile. Up to 40% of untreated patients with essential hypertension and many patients with borderline hypertension already have lipid abnormalities, such as elevated LDL-C and a decrease in HDL-C levels. 22 In a study from 13 English general practices, 23 over 85% of the hypertensive patients had TC levels 45.2 mmol/l (200 mg/dl). Moreover, about 65% had levels 46.0 mmol/l (232 mg/dl) (which doubles the risk of a CHD event), the mean level was approximately 6.5 mmol/l (251 mg/dl).
There is also evidence that a significant proportion of hypertensive patients have other lipid abnormalities associated with the metabolic syndrome, such as low HDL-C and high TG concentrations. 5, 24 Similarly, in a Japanese study, 25 a review of the profiles of 830 hypertensive patients revealed a diagnosis of hyperlipidaemia in more than 45%. Of these, less than 65% were on any lipid-lowering treatment and less than 40% reached lipid target levels. 25 Genetic studies in humans and animal models suggest that a predisposition for the development of both hypertension and dyslipidaemia may result from the inheritance of shared genetic risk factors. 18, 26 In spontaneously hypertensive mice, Bottger et al. 26 showed that the genes responsible for BP regulation and those linked to an increased propensity for dyslipidaemia were located in the same three general areas of chromosomes 8, 19 and 20. Among population-based sibships in Utah (USA) with essential hypertension diagnosed before the age of 60 years, the prevalence of familial combined dyslipidaemia was 10 times that of the general population. 18, 27 This subgroup of patients with hypertension and associated lipid abnormalities was termed familial dyslipidaemic hypertension. Studies in subjects with familial combined hypercholesterolaemia showed that hypertension is present in as much as 30-40% of patients, thus suggesting a lower penetrance for hypertension compared to dyslipidaemia in this group. 28, 29 However, although lipid-lowering (statins or fibrates) treatment is commonly introduced in patients with familial combined hypercholesterolaemia, the effect of these drugs on BP in these patients is not documented.
In genetic mapping studies of hypertension involving kindreds with familial combined hypercholesterolaemia, a quantitative trait linkage of sodium-lithium countertransport (SLC, a membrane transport marker associated with hypertension and insulin resistance) activity to human chromosome 4p in the region containing a fatty acid hydrolase (CD36) and a-adducin has been shown. 28, 29 Furthermore, secondary loci for SLC have been identified in chromosome 8p close to the lipoprotein lipase gene and for diastolic BP in chromosome 19 close to the apolipoprotein B locus. 28 Ferrari et al. 30 showed that young normotensives in apparently good health, but with one essential hypertensive parent, tend to have an impairment of insulin-mediated glucose disposal, hyperinsulinaemia and dyslipidaemia. The investigators suggested that a familial trait for essential hypertension seems to coexist with defects in carbohydrate and lipoprotein metabolism. These defects can be detected at an early age and before or at least at a very early stage of the development of high BP. 17, 30 In a study of 1577 individuals randomly selected from the general population, Pereira et al. recently reported significant interactions between the nitric oxide (NO) synthase (eNOS) Glu298Asp gene variant and TC (P ¼ 0.02), log-transformed TGs (P ¼ 0.004) or non-HDL-C (P ¼ 0.003) in the determination of systolic BP. 31 The authors suggest that these results provide evidence supporting the role of the eNOS Glu298Asp gene variant in modulating BP through a relationship with lipid levels. 31 Statins and blood pressure: data from experimental studies The importance of lowering plasma cholesterol to reduce the incidence of vascular events is well established. The key role of statins in the management of patients with increased risk of cardiovascular disease is widely accepted. Although, control of hypertension has been unanimously considered of principal importance in the prevention of stroke, there is also evidence that lipid-lowering therapy (namely statins) significantly decreases stroke risk. [32] [33] [34] Among lipid-regulating agents, statins are the most widely studied drugs. In addition to their lipid-lowering effects, other beneficial properties (referred to as 'pleiotropic effects') have been recognised. 35 There are scarce experimental data regarding the direct effect of statins on BP. Lovastatin has been shown to reduce BP in spontaneous hypertensive rats (SHR, an experimental model widely used for the study of essential hypertension). Jiang et al. 36 evaluated the effects of lovastatin on renal function and the development of hypertension in SHR. Fourweek-old SHR were given lovastatin (10 mg/kg) or vehicle twice daily by gavage. After 4 weeks of treatment, mean arterial BP was significantly lower in the lovastatin-treated SHR (n ¼ 5) compared with the control (n ¼ 12) animals (13174 vs 16074 mm Hg, Po0.05). The decrease in arterial BP in the lovastatin-treated rats was accompanied by changes in renal function. The slope of the relationship between arterial BP and sodium excretion was threefold greater in lovastatin-treated SHR than in control rats, and this was associated with significant elevations in renal medullary blood flow and renal interstitial hydrostatic pressure. Glomerular filtration rate was 17% higher in the lovastatin-treated SHR than in controls (0.9470.05 vs 0.8170.07 ml/ min per g of kidney weight, Po0.05). The wall-tolumen area ratio of renal arterioles was significantly reduced in lovastatin-treated SHR compared with vehicle-treated rats (0.8670.05 vs 1.0870.04 for vessels with inner diameters o50 mm and 0.6270.02 vs 0.7570.04 for vessels with inner diameters of 50-100 mm, Po0.05). These results indicate that chronic treatment with lovastatin shifts the relations between renal medullary blood flow, renal interstitial pressure, sodium excretion and renal perfusion pressure to lower levels of arterial pressure and attenuate the development of hypertension and hypertension-induced renal vascular hypertrophy in SHR. 36 In a model of cerebral blood flow (CBF) autoregulation, Regriny et al. 37 assessed the structure and mechanics of cerebral arterioles and the lower limit of CBF autoregulation in SHR untreated or treated with lovastatin (20 mg/kg per day) for 1 month. Lovastatin significantly reduced mean arterial BP (15373 mm Hg in treated vs 17175 mm Hg in untreated, Po0.05) and normalised the cross-sectional area of the vessel wall in maximally dilated cerebral arterioles (treated: 826752 vs untreated: 1099716 mm, 2 Po0.05). Lovastatin also attenuated the increase in passive distensibility, but had no effect on the external diameter of cerebral arterioles or the lower limit of CBF autoregulation. 37 In an experimental model involving Dahl saltsensitive rats (Dahl S, a model of salt-sensitive hypertension), pravastatin treatment reduced the severity of hypertension and renal damage (proteinuria and glomerular injury). 38 Moreover, in a mouse model of salt-dependent hypertension chronic treatment with lovastatin (40 mg/kg body weight) and bezafibrate (50 mg/kg body weight) diminished deoxycorticosterone acetate (DOCA)-salt-induced reductions in total renal blood flow. Lovastatin improved medullary blood flow (130% increase of baseline values) reactions to increased perfusion pressure or to volume expansion and resulted in a significant decrease of systemic BP in DOCA-salt mice. 39 Chronic treatment with cerivastatin (2 mg/kg per day by gavage) prevented or retarded hypertensioninduced renal injury via inhibition of renal fibrosis and proteinuria in stroke-prone SHR and inhibited the expression of transforming growth factor-b1 in the kidneys. 40 Cerivastatin has also been shown to protect against hypertension-based stroke and ameliorate the disease severity. Kawashima et al. 41 showed that chronic treatment of stroke-prone SHR resulted in a significant decrease in the incidence and size of stroke and early mortality. These effects were independent of BP and lipid levels. Statin treatment significantly reduced superoxide production from non-stroke parenchyma of the brain and infiltration of inflammatory cells to the stroke lesions. 41 In another experimental model of strokeprone SHR, 42 atorvastatin decreased the BP, at least in part via the reduction of sympathetic nervous system activity. This so-called 'sympatho-inhibitory effect' may be mediated by an increase in NO production, with the upregulation of eNOS expression in the brain. 42 In another study, Susic et al. 43 evaluated the effects of rosuvastatin on systemic and regional haemodynamics in two hypertensive rat models (one genetically determined, and the other hypertensive-induced via inhibition of NO synthesis). Rosuvastatin reduced arterial BP in SHR rats and decreased total peripheral resistance. Regional haemodynamics improved with rosuvastatin in both hypertensive models, as evidenced by increased blood flows and decreased vascular resistance.
These effects were independent of changes in plasma lipids. 43 Statin treatment may favourably affect vascular endothelium in the hypertensive state. Ge et al. 44 showed that atorvastatin can improve vascular remodelling of the thoracic aorta in SHR. Indeed, treatment with atorvastatin produced a significant reduction of systolic BP of caudal artery (Po0.01) combined with significant reductions in serum concentrations of TC, TGs and HDL-C compared with the non-atorvastatin-treated group. Wall thickness media thickness and medial cross-sectional area to lumen ratio were significantly lower in the atorvastatin-treated group (Po0.05).
Statins and blood pressure: data from clinical trials The effect of statin treatment on BP was studied in a wide range of patients, including normotensive subjects, hypertensive, normolipidaemic, hyperlipidaemic and diabetic patients, as well as combinations of these groups. [45] [46] [47] [48] Both neutral and favourable effects on BP levels have been reported with all HMG-reductase inhibitors (Table 1) .
Sung et al. 20 evaluated the systemic effects of elevated cholesterol on BP and BP reactivity. The BP response to provoked stress (induced by a standard mental arithmetic test (MAT)) was examined in 37 healthy, normotensive HC subjects and 33 normolipidaemic controls. HCs had slightly higher systolic BP at baseline (122 vs 118 mm Hg, Po0.05) and systolic BP response during MAT (1878 vs 1075 mm Hg, Po0.05) than controls. Maximal changes in systolic BP were significantly correlated with cholesterol (r ¼ 0.41, Po0.001), whereas heart rate and diastolic BP changes were unrelated to serum cholesterol. To confirm that BP reactivity was dependent on cholesterol, the MAT was repeated after treatment with using a crossover design in 26 HC subjects. Lovastatin (20 mg/day for 6 weeks) significantly improved lipid profiles (À26% TC, þ 8% HDL-C, À34% LDL-C) and resulted in a small nonsignificant decrease in systolic BP at baseline (À3 mm Hg) and a significantly lower systolic BP (À8 mm Hg, Po0.05) during the MAT. 20 In two open-label clinical studies 49, 50 involving 49 and 23 hypertensive HC patients, respectively, a significant fall in systolic (mean arterial systolic BP was reduced from 147716 to 142715, and from 145714 to 139718 mm Hg, respectively) and diastolic BP (mean arterial diastolic BP was reduced from 9579 to 8878, and from 9779 to 92711 mm Hg, respectively) was observed after 12 weeks of treatment with fluvastatin. 49, 50 In another study, 51 30 subjects with moderate hypercholesterolaemia and untreated hypertension (systolic and diastolic BP 14976 and 9772 mm Hg, respectively) were randomised in a double-blind manner to placebo or pravastatin (20-40 mg/day) in a crossover design. In the 25 participants who completed the 32-week trial, pravastatin significantly decreased TC and LDL-C (P ¼ 0.001), systolic and diastolic BP (À8 and À5 mm Hg, both P ¼ 0.001), and pulse pressure (À3 mm Hg, P ¼ 0.011), and blunted the BP increase caused by the cold pressor test (À4 mm Hg, P ¼ 0.005) compared with placebo. A significant reduction in circulating endothelin-1 levels was also seen in the pravastatin-treated patients. 51 Simvastatin improved lipid abnormalities in patients treated for hypertension, and produced an additional nonsignificant fall (À5.2 mm Hg) in systolic BP levels. 52 The potential effects of simvastatin on BP and urinary albumin excretion beyond its capacity to lower serum cholesterol were evaluated in 26 microalbuminuric hypertensive type II diabetic patients (diastolic BP consistently 490 ando100 mm Hg; plasma LDL-C43.9 and o6.5 mmol/l (4151 and o251 mg/dl)). 53 In random order, these patients received simvastatin (20 mg/day) or cholestyramine (6 g three times a day) for a period of 10 months, and after 3 months of wash-out (crossover), the sequence was reversed for an additional 10 months. Simvastatin and cholestyramine were equally effective in reducing TC and LDL-C. However, only during simvastatin treatment, a significant reduction in diastolic BP (from 9773 to 9173 mm Hg, Po0.01) and both 24 h urinary albumin and glycosaminoglycan (a marker of renal injury) excretion rates were observed, whereas no significant changes were seen with cholestyramine treatment. These findings are indicative of an antihypertensive effect of simvastatin independently of its cholesterol-lowering capacity. 53 In a randomised, double-blinded, cross-over study, 54 22 patients with isolated systolic hypertension (ISH) received 3 months of atorvastatin therapy (80 mg/day, that is, intensive hypolipidaemic treatment) and 3 months of placebo treatment. Besides a 48% decrease in LDL-C levels, atorvastatin reduced brachial systolic BP (14872 vs 15473 mm Hg in the placebo group, P ¼ 0.03), mean BP (10772 mm Hg vs 11172, P ¼ 0.04) and diastolic BP (8172 vs 8371 mm Hg, P ¼ 0.04). 54 In addition to their beneficial effects on lipid abnormalities in kidney transplant patients, statins have proved efficient antihypertensives by reducing systolic, diastolic and mean arterial BP by 7 mm Hg (P ¼ 0.005), 3 mm Hg (P ¼ 0.05) and 4 mm Hg (P ¼ 0.007), respectively, after 12 months of treatment. In a study involving 113 stable kidney graft recipients, patients on statins had lower systolic, diastolic and mean BP measurements (P ¼ 0.05, 0.03 and 0.02, respectively) at 12 months compared with non-statin-treated controls. These findings were independent of lipid-lowering associated with statin treatment. 55 In another study, 56 hypertensive and normotensive subjects with hypercholesterolaemia were randomised to receive a statin (n ¼ 51, simvastatin 10-20 mg/day, pravastatin 10-20 mg/day or atorvastatin 5-10 mg/day) or placebo (n ¼ 23) for 2 months. Statin-treated hypertensive subjects showed lower systolic and diastolic ambulatory BP (À5.775.8 and À3.573.9 mm Hg, respectively, both Po0.001).
56
This effect was unrelated to the concomitant cholesterol reduction. 56 In contrast, no effect was observed in normotensive subjects. 56 Hypertensive and dyslipidaemic subjects (n ¼ 32) were treated with atorvastatin (20 mg/day) in one study. 57 In the Brisighella Heart Study, 59 a total of 1356 HC subjects were randomly treated for 5 years with either low-fat diet, cholestyramine, gemfibrozil or simvastatin. Participants were divided at baseline into four quartiles according to systolic BP. A significant decrease in BP was observed in the two upper quartiles of systolic BP and was greater in subjects treated with cholesterol-lowering drugs. 59 In particular, the BP reduction was greater in patients treated with a statin despite comparative reductions in LDL-C (reduction by 13% in both systolic and diastolic BP at the highest quartiles after 5 years of treatment with a statin vs 10% after treatment with non-statin drugs, Po0.005).
59
The BP-lowering effect of statins is not a consistent finding in all studies. Thus, 16-week simvastatin treatment in HC normotensive patients with insulin-dependent diabetes mellitus did not affect body weight, BP or glycaemic control. 60 Similarly, simvastatin had no effect on BP, heart rate or body weight in HC normotensive elderly patients. 61 Pravastatin (40 mg daily for 8 weeks) in normotensive patients with primary hypercholesterolaemia had no effect on BP, heart rate, cardiac function and systemic vascular resistance. 62 In a study of 213 hypertensive HC patients, BP levels were not influenced by chronic lovastatin treatment (10-80 mg daily for 6 months). 63 Moreover, in a recent study, 64 85 hyperlipidaemic hypertensive subjects whose BP was insufficiently controlled by antihypertensive treatment were randomised to receive pravastatin, fluvastatin, simvastatin or a non-statin hypolipidaemic drug for 12 months. No effect on BP was observed in either of these groups. 64 This is the only single-blind randomised prospective study designed to compare the longterm effects of different statins (a head-to-head comparison between one hydrophilic (pravastatin) and two lipophilic drugs (simvastatin and fluvastatin)) on BP control in hypertensive patients with high cholesterol levels. 64 Although a beneficial effect of statins on BP was seen in the majority of studies, the question whether these reductions in systolic and diastolic BP are clinically relevant remains to be answered. Generally, statin treatment is associated with a decrease of 5-8 mm Hg in systolic BP and a 3-5 mm Hg decrease in diastolic BP. These reductions are comparable with those achieved in some long-term studies using antihypertensive agents. Therefore, we can presume that the statin-induced BP changes are clinically relevant. Nevertheless, long-term, large-scale studies are necessary in order to evaluate this phenomenon. Moreover, it appears that hypertensive subjects are more responsive to LDL-C reduction compared with normotensives; whether this is a nonspecific effect owing to higher baseline values or a specific pathophysiological mechanism remains to be answered.
It is of interest to overview the findings of large landmark statin trials where statins were prescribed for long periods to diverse subgroups in primary and secondary prevention (Table 2 ). It appears that the overall benefit in cardiovascular risk reduction was similar among subjects/patients with or without hypertension; in a recent meta-analysis of data from 90 056 participants in 14 randomised statin trials, major vascular event reduction per mmol/l of LDL-C decrease was not different between patients with treated hypertension (RR 0.81) or not (RR 0.77), as well as between participants with diastolic BPp90 mm Hg (RR 0.79) and those with diastolic BP490 mm Hg (RR 0.77). 65 Although a sizable number of hypertensive subjects were included in these studies, there is no report as to whether statin treatment produced any significant BP reductions. The most probable explanations for the absence of an antihypertensive effect associated with statin therapy in the landmark statin trials could be summarised as follows:
The influence of statin treatment on BP was not included in the study design. A beneficial effect on BP in hypertensive patients could have been attenuated by a large numbers of normotensive participants, in whom no effect occurred. Antihypertensive drugs may have masked any beneficial effect of statins.
Reduction in blood pressure owing to statin therapy: pathophysiological mechanisms In the statin studies demonstrating a beneficial effect on BP, there was no correlation between the decrease of BP and the changes in plasma TC and LDL-C levels. This observation is in favour of a nonlipid-lowering mechanism being responsible for the antihypertensive action of these agents (Table 3) . On the other hand, there are only scarce data showing reductions in BP levels achieved by other classes of hypolipidaemic agents. These statin-specific actions are probably part of the so-called 'pleiotropic effects' of this class of drugs and may account for the CVD protection related to statin treatment. 35 However, there is a paucity of randomised, placebo-controlled studies with reference to the BP-lowering effect of statins in relation with their anticipated LDL-C lowering effect.
Effects on endothelial dysfunction and nitric oxide synthesis. The vascular endothelium is a dynamic endocrine organ that regulates contractile, secretory and mitogenic activities in the vessel wall and haemostatic processes within the vascular lumen. 66 Endothelial dysfunction is present in patients with hypertension, diabetes mellitus, insulin resistance and dyslipidaemia. Lipid-lowering treatment improves endothelial function. The endotheliumderived relaxing factor, NO, is thought to be the key mediator of these beneficial effects. Statins appear to restore or improve endothelial function by increasing the bioavailability of NO, promoting re-endothelialisation, reducing oxidative stress and inhibiting inflammatory responses. 66, 67 Laufs et al. 68 demonstrated a direct effect of lovastatin and simvastatin on constitutive eNOS protein mass and messenger RNA levels in endothelial cells of the human saphenous vein exposed to oxidised LDL. Simvastatin reversed, in a dosedependent manner, the inhibitory effect of oxidised LDL on L-NG-monomethyl arginine (L-NMMA) inhibitable nitrite production (L-NMMA is a specific inhibitor of endothelium-derived NO). At high statin concentrations, nitrite production exceeded levels observed in the absence of oxidised LDL. The authors further demonstrated that this effect was caused by an increased stability of eNOS mRNA induced by the statin. 68 These findings are in agreement with experimental studies showing improvement of focal cerebral ischaemia following statin treatment. 141 Pravastatin was used in WOSCOPS, CARE, LIPID and PROSPER trials; lovastatin was used in AFCAPS/TexCAPS; simvastatin was used in 4S, HPS and IDEAL; and atorvastatin was used in ASCOT-LLA, CARDS, TNT and IDEAL. 
Statins and hypertension HJ Milionis et al
Data from the Framingham study have implicated pulse pressure as major cardiovascular risk factor, especially in the elderly. 70 Pulse pressure is raised as a result of rapid pulse wave reflection in stiffer arteries leading to the development of ISH, which affects about 25% of the population older than 55 years of age. 29, 71 The association between pulse wave velocity, hypertension and cardiovascular disease risk has been repeatedly demonstrated in several studies. 29, 72, 73 In addition to antihypertensive agents, lipid-lowering drugs (especially statins) favourably affect pulse wave velocity. In a study involving 22 normolipidaemic patients with ISH, atorvastatin (80 mg/day for 3 months) had a beneficial effect on large artery stiffness and BP. 54 Similarly, aortic stiffness was reduced in men after treatment with atorvastatin. 74 In addition to the reduction of LDL-C levels and brachial systolic, mean and diastolic BP, atorvastatin caused an increase in systemic arterial compliance (atorvastatin vs placebo: 0.4370.05 vs 0.3670.03 ml/mm Hg, P ¼ 0.03). 54 Atorvastatin has also been shown to increase aortic pulse wave velocity in hypertensive HC patients. 75 There is evidence that statins exert their favourable effects on the endothelium within 24 h. 76, 77 For example, in a short-term study in CHD patients, pravastatin 40 mg improved endothelium-dependent coronary vasomotion within 24 h in the absence of any significant reduction of cholesterol or C-reactive protein levels. 76 Effect on endothelin. Endothelial vasoreactivity is a complex process and involves many molecules besides NO. Another way to improve blood flow would be to inhibit the production of a potent endothelial-derived vasoconstrictor, endothelin-1. Animal studies suggest that endothelin plays a role in certain models of hypertension. 78, 79 The applicability of these findings to hypertension in humans is uncertain, but an increasing number of studies suggest that endothelin antagonists will be clinically useful. 80, 81 Plasma endothelin levels are usually normal in hypertensive subjects 78 ; however, there may be an increase in sensitivity to endothelin in essential hypertension. 82 Hernandez-Perera et al. 83 showed that both atorvastatin and simvastatin reduced in a dose-and time-dependent manner, the pre-pro expression of endothelin-1 mRNA (60-70% maximum inhibition) and endothelin-1 synthesis in bovine aortic endothelial cells in vitro. Pravastatin reduced the circulating levels of endothelin-1 in patients with essential hypertension and primary hypercholesterolaemia. 51 However, in the Reduction of Cholesterol in Ischemia and Function of Endothelium (RECIFE) trial, 84 pravastatin had no effect on plasma endothelin-1 after 6 weeks of treatment, and this was also true with fluvastatin given over a period of 6 months. 85 Effect on the renin-angiotensin system. Experimental data underline the role of vascular reninangiotensin systems in mediating the early stages of vascular endothelial dysfunction and inflammation as prerequisites for unleashing the cascade of cellular and molecular events that lead to the deposition of foam cells and their eventual progression to the atherosclerotic plaque. 86 Statins may cause vasodilation by correcting endothelial dysfunction, which frequently accompanies hypertension and hypercholesterolaemia. In this respect, pravastatin has been shown to decrease endothelial reactivity responses (assessed by BP measurement) to incremental infusions of angiotensin II or norepinephrine. 87 The role of aldosterone as part of the reninangiotensin aldosterone system in the development and maintenance of hypertension is well documented. Although plasma aldosterone is an erratic parameter to determine, there is some evidence that statins may lower circulating aldosterone levels. 88 Hypercholesterolaemia is associated with an overexpression of angiotensin II type 1 (AT1) receptors in experimental models and in humans, leading to a significant increase of angiotensin-II-induced BP elevation. There is evidence that statins downregulate AT1 receptor expression. 67, 89 Nickenig et al. 89 showed that AT1 receptor expression is significantly enhanced in HC compared with normocholesterolaemic individuals, whereas statin treatment attenuated the elevated BP response to angiotensin II infusion and downregulated AT1 receptor density.
Other potential mechanisms of action. The experimental model of rat genetic hypertension has been considered as a valuable tool to investigate the pathophysiological interactions between hypercholesterolaemia and hypertension, as it is free from the confounding effects of other risk factors or atherosclerosis and does not exhibit the extreme heterogeneity of the human disease. It has been shown that dietary lipids may affect sodium handling and the development of hypertension. 90 Cholesterol enrichment in renal cellular membranes may decrease sodium efflux along the nephron, consequently reducing the fractional clearance rate of sodium and favouring its retention. There is also evidence that hypercholesterolaemia exerts a significant influence on adrenal steroid metabolism in SHR.
In particular, in an experimental study, a three-fold increase in plasma cholesterol was associated in these animals with a notable increase in aldosterone and a reduction of corticosterone that resulted in a marked rise of the mineralocorticoid/glucorticoid ratio. 91 In addition, the urinary sodium excretion ratio was reduced. 91 The effects of hypercholesterolaemia on adrenal steroids as well as water and salt metabolism were reversible following withdrawal of the high cholesterol diet, implying a potential role for cholesterol-lowering treatment. In line with this concept, in patients with primary hyperlipidaemia, atorvastatin 40 mg daily was reported to increase the urinary excretion of sodium in conjunction with an increase in renal excretion of uric acid. 92 Another interesting issue involves voltage-gated calcium influx through L-type Ca 2 þ channels, which regulate the diameters of small arteries and arterioles, and maintains the myogenic tone of resistance vessels and contribute to the pathogenesis of hypertension. 93 Diet-induced hypercholesterolaemia has been reported to alter the activity of several smooth muscle membrane channels and pumps, including voltage-gated calcium channels and sodium/potassium ATPase, 94 an effect that has been attributed to changes in membrane-free cholesterol content. 95 Indeed, animal studies have showed an inverse relationship between membrane free cholesterol content and L-type Ca 2 þ channel-pump activity. 96 Thus, statin treatment may inhibit calcium influx leading to vascular smooth muscle relaxation and subsequent lowering of BP. 97 Effects of managing serum lipids and hypertension on cardiovascular risk There is convincing evidence that treating hypertension is associated with a reduction in stroke and a less prominent decline in the incidence of CHD-related events. 98, 99 It is also well known that elevated serum cholesterol levels significantly increase CHD risk. Therefore, it seems logical that coexisting cardiovascular risk factors including abnormal lipid profiles should be an integral part of hypertension management.
Support for correcting both hyperlipidaemia and hypertension comes from the Gothenburg Primary Prevention Study, 100 which showed that coronary risk is not greatly reduced when BP is lowered, whereas serum cholesterol rises. However, patients in whom both BP and serum cholesterol were reduced benefited the most in terms of CHD risk reduction. The Helsinki Heart Study also demonstrated that effectively treating hypertension in hypertensive, dyslipidaemic men (primarily with diuretics and beta-blockers) reduced the risk of CHD events by more than 50% when compared to those with persistent hypertension. 101 Similarly, in the Greek Atorvastatin and Coronary heart disease Evaluation (GREACE) trial 102 atorvastatin þ angiotensin-converting enzyme (ACE) inhibitors produced significantly better results than either drugs alone or none of these drugs.
The benefit of lowering both BP and cholesterol was evaluated in two large-scale trials, ALLHAT 103 and ASCOT-LLA. 34 Part of the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) study was designed to determine whether pravastatin compared with usual care reduces all-cause mortality in hypertensive, moderately HC patients with at least one additional CHD risk factor. A total of 10 355 ambulatory patients, aged X55 years, with an LDL-C of 3.1-4.9 mmol/l (120-189 mg/dl) or 2.6-3.3 mmol/l (100-129 mg/dl) for CHD patients and TGs o3.95 mmol/l (350 mg/ dl), were randomised to pravastatin (40 mg/day; n ¼ 5170), or usual care (n ¼ 5185). Mean age was 66 years; 49% were women; 14% had a history of CHD and 35% type II diabetes. At 4 years, TC was reduced by 17.2% with pravastatin vs 7.6% with usual care. All-cause mortality was similar in the two groups (RR ¼ 0.99; 95% CI: 0.89-1.11; P ¼ 0.88), with 6-year mortality rates of 14.9% in the pravastatin-treated group and 15.3% in the group receiving usual care. CHD event rates were not different between the two groups (RR ¼ 0.91; 95% CI: 0.79-1.04; P ¼ 0.16); 6-year CHD event rates were 9.3% (pravastatin) and 10.4% (usual care), respectively. These results could be attributed to the small difference in TC (9.6%) and LDL-C (16.7%) between pravastatin and usual care compared with other statin trials. The need for aggressive lowering of LDL-C levels was clearly demonstrated in recent clinical trials. [104] [105] [106] [107] [108] [109] In the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA), 110 19 342 men and women with hypertension and at least three other cardiovascular risk factors were randomised to amlodipine (5-10 mg/ day)7perindopril (4-8 mg/day) or to atenolol (50-100 mg/day)7bendroflumethiazide (1.25-2.5 mg/ day). A total of 10 305 of these patients with normal or slightly elevated TC were randomised to atorvastatin 10 mg/day or placebo (Lipid-Lowering Arm). 34 The atorvastatin arm was prematurely stopped at 3.3 years owing to a significant 36% reduction (P ¼ 0.0005) in the primary end point. Benefits were apparent within the first year of treatment. Fatal/ non-fatal stroke (89 atorvastatin vs 121 placebo, RR ¼ 0.73, 95% CI: 0.56-0.96, P ¼ 0.024) and total cardiovascular/coronary events (178 vs 247, RR ¼ 0.71, 95% CI: 0.59-0.86, P ¼ 0.0005) were also reduced with atorvastatin. At 1 year, atorvastatin reduced TC and LDL-C by 24 and 35%, respectively. It is particularly relevant that there was a significant reduction in stroke despite very good BP control. 34 Treating the hypertensive hyperlipidaemic patient An essential component of the management of the hyperlipidaemic hypertensive patient is dietary and lifestyle advice. In addition to the standard nonpharmacological interventions (reduction in salt and alcohol intake), these patients require advice to reduce saturated fat, cholesterol and total caloric intake and increase exercise. Lifestyle modification should be recommended in the management of both hypertension and dyslipidaemia. [111] [112] [113] [114] Lipidfriendly (e.g. alpha-blockers) or lipid neutral (calcium antagonists, ACE inhibitors, angiotensin II receptor antagonists 115 ) may be considered in the context of hypertension and dyslipidaemia. In addition, an extra BP-lowering effect may be anticipated by lipid-lowering interventions. It is also of interest that lipid-friendly and lipid neutral antihypertensives may also exert beneficial haemostatic effects when compared with lipid hostile BP-lowering drugs. 116, 117 Combination therapy is of major interest in the management of high-risk patients with dyslipidaemia. Statins (pravastatin) plus ACE inhibitors (captopril) were shown to have additive effects on atherosclerosis reduction in hyperlipidaemic hamsters. 118 In another study, pravastatin, but not probucol, had an additional BP-lowering effect in patients receiving antihypertensive therapy. 119 In fact, systolic BP was significantly decreased after pravastatin treatment (from 141.274.7 to 136.575.3 mm Hg, Po0.001), whereas no significant changes were noted in diastolic BP levels (from 81.374.9 to 80.675.1 mm Hg). 119 In a 14-week, open, three-phase design study, carried out on 30 HC, hypertensive subjects, Nazzaro et al. 120 found that simvastatin (10 mg daily) and enalapril (20 mg daily) had similar, distinct and combined vascular effects. Stress-induced and postischaemic forearm blood flow and HDL-C levels were significantly increased and vascular resistance lowered by both drugs. A significant additive effect was also observed on levels of LDL-C, HDL-C and BP, as well as on vascular damage (as reflected by a decrease in minimal vascular resistance). Furthermore, simvastatin monotherapy lowered diastolic BP modestly but significantly (À5% compared with À10% with enalapril). 120 In another study, Sposito et al. 121 aimed at lowering diastolic BP at levels o95 mm Hg with enalapril and lisinopril in 70 HC hypertensive patients, half of whom were treated with either pravastatin or lovastatin in order to achieve similar target concentrations of plasma TC (o5.2 mmol/l (200 mg/dl)). After 16 weeks, but not after 4 weeks of treatment, the statin þ ACE inhibitor-treated group had a greater reduction in diastolic BP compared with the group receiving ACE inhibitor monotherapy. The diastolic BP reduction correlated with changes in TC (r ¼ 0.87, P ¼ 0.013). Reductions in systolic BP were greater on combination therapy from the second week, but did not correlate with TC reduction. From baseline levels averaging 118 mm Hg, the mean BP was reduced to 9774 mm Hg after 16 weeks of treatment in the combination group (À1872%, Po0.01) and 10477 mm Hg in the enalapril monotherapy group (À1271%, Po0.01).
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Statin plus antihypertensive drugs combination treatment has a favourable additive effect on inflammation, arterial compliance and vascular smooth muscle cell proliferation mediated by AT1 receptors. [122] [123] [124] The addition of a statin has also been shown to have an additional effect on reducing left ventricular mass (a powerful predictor of cardiovascular events) in patients with systemic hypertension and hyperlipidaemia on antihypertensive agents and diet. 125 In this context, the Hypertension High Risk Management (HYRIM) 126 trial investigated the effects of fluvastatin and lifestyle intervention in drug-treated hypertensive patients with the primary end point being carotid intima-media thickness (IMT) progression over 4 years. Hypertension High Risk Management also investigated the effect of fluvastatin on the development of left ventricular hypertrophy (LVH). Hypertension High Risk Management was a randomised, placebo-controlled 2 Â 2 factorial trial. Dyslipidaemic middle-aged men (n ¼ 568) on treatment for hypertension were randomly assigned to receive either fluvastatin 40 mg/day or placebo and either intensive lifestyle intervention or usual care. Fluvastatin significantly reduced common carotid IMT progression compared with placebo and usual care, whereas lifestyle intervention alone had no significant effect on carotid IMT progression in patients receiving either fluvastatin or placebo treatment. Fluvastatin treatment significantly (P ¼ 0.0144) retarded the development of LVH compared with placebo. 126 On the other hand, in an experimental model of NO-deficient hypertension, simvastatin monotherapy improved NO production and partially prevented the development of hypertension via attenuation of the inhibition of eNOS, but had no significant effect on left ventricular mass or aorta remodelling. 127 Renal function, hypertension, lipids and statins The association between renal function and hypertension is well established. 6, 36, [38] [39] [40] 53 This association may also be influenced by lipid changes occurring in patients with renal disease and who also have a raised BP, as discussed above. 6, 36, [38] [39] [40] 53 The contribution of lipids to the renal functionhypertension association may at least in part explain why statins exert beneficial effects on both renal function and hypertension. 6, 36, [38] [39] [40] 53, 128 It is also relevant that recent trials have shown that aggressive treatment with statins improves serum creatinine and urate levels. [129] [130] [131] [132] [133] [134] [135] [136] [137] These findings probably reflect an improved creatinine clearance. In turn, this effect is probably another consequence of improved blood flow following treatment with statins. Serum creatinine and urate levels may also be considered as predictors of vascular risk. 129, 138 Thus, the beneficial effects of statins in hypertensive patients may involve several mechanisms, especially if they have hyperuricaemia and impaired renal function (even when creatinine levels are at the upper limit of the reference range).
Concluding remarks
Large-scale intervention trials have shown a strong cardiovascular protective effect of statins that even extends to patients with normal serum cholesterol levels. It is therefore believed that in addition to lipid lowering, other properties contribute to statininduced cardiovascular protection. Several clinical studies have been conducted to verify whether or not statin treatment is associated with a reduction in arterial BP, which would account for a further cardiovascular protective potential of these drugs. A small but possibly clinically relevant reduction in BP levels associated with statin therapy has been reported in a number of studies. Relatively small groups of patients, technical issues in BP measurement, a possible heterogeneity of the BP effect of statins in different subjects (e.g. male vs female patients, young vs old, normo-vs hyper-cholesterolaemic and normo-vs hyper-tensive patients) may account for any discrepancies. This BP-lowering effect is primarily observed in hypertensive patients. However, it is not clear why normo-and hyper-tensive patients benefited the same in statin trials. 65 The favourable effect of statins on BP is probably mediated by mechanisms that are independent from a direct effect on LDL-C levels. Combination treatment with statins and drugs that primarily act through restoration of vascular endothelial function, such as ACE inhibitors or angiotensin II receptor antagonists, may provide additional benefit in patients at high cardiovascular risk.
It is currently understood that cardiovascular disease risk management requires a holistic response to a variety of vascular risk factors. 139, 140 Hypertension and hyperlipidaemia not only coexist but seem to be interrelated and share common pathophysiological pathways. Hypertension and hyperlipidaemia should be addressed in a concerted manner taking into account the beneficial properties of certain drugs used to treat either condition.
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